Study of Novel Treatment Combinations in Patients With Lung Cancer

Key Inclusion Criteria:

All Substudies:

• Histologically or cytologically documented non-small-cell lung cancer (NSCLC).

• No known actionable genomic alterations for which targeted therapies are available.

• Eastern cooperative oncology group (ECOG) performance status score of 0 or 1.

• Measurable disease per response evaluation criteria in solid tumors.

• Adequate hematologic and end-organ function.

• Individuals of childbearing potential who engage in heterosexual intercourse mustagree to use specified method(s) of contraception.

Substudy 01: All Experimental arms

• Stage IV NSCLC.

• For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR)or anaplastic lymphoma kinase (ALK) alteration negative.

• PD-L1 status by central confirmation.

• No prior systemic treatment for metastatic NSCLC.

Substudy 02: All Experimental arms

• Stage IV NSCLC.

• In individuals with nonsquamous histology and actionable EGFR, ALK, or other knowngenomic alterations must have received treatment with at least 1 targeted therapy tothe appropriate genomic alteration.

Substudy 03: All Experimental arms

• Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2)NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).

• Planned surgery must comprise of lobectomy, sleeve lobectomy, or bi-lobectomy.

• PD-L1 status by central confirmation.

• For individuals with nonsquamous histology: Epidermal growth factor receptor (EGFR)or anaplastic lymphoma kinase (ALK) alteration negative.

Key Exclusion Criteria:

All Substudies:

• Mixed small-cell lung cancer and NSCLC histology.

• Active second malignancy.

• Active autoimmune disease.

• History of or current non-infectious pneumonitis/interstitial lung disease.

• Active serious infection within 4 weeks prior to study treatment.

Substudy 01 and 02

• Known active central nervous system (CNS) metastases and/or carcinomatousmeningitis.

• Received previous anticancer therapy within 4 weeks prior to enrollment.

Substudy 03: All Experimental arms

• NSCLC previously treated with systemic therapy or radiotherapy.

• Received prior treatment with any anti-PD-(L)-1 or other immune checkpointinhibitors (CPIs).

Note: Other protocol defined inclusion/exclusion criteria may apply